Belite Bio, Inc
BLTE
शेयरों में रैंक
#3102
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
शेयर मूल्य
$145.23
मार्केट कैप
$5.85B
बदलाव (1 दिन)
1.72%
बदलाव (1 वर्ष)
65.58%
देश
US
व्यापार Belite Bio, Inc (BLTE)
श्रेणी
Healthcare
Belite Bio, Inc (BLTE) के लिए EPS
June 2026 TTM तक का EPS: $-2.76
Belite Bio, Inc की नवीनतम वित्तीय रिपोर्टों और शेयर मूल्य के अनुसार, कंपनी का वर्तमान EPS (TTM) $-2.76 है। 2023 के अंत में, कंपनी का EPS $-1.19 था, जो 2022 के EPS $-0.63 के की वृद्धि था।
Belite Bio, Inc के लिए 2020 से 2026 तक का EPS इतिहास
प्रत्येक वर्ष के अंत में EPS
| वर्ष | EPS | परिवर्तन |
|---|---|---|
| 2026 (TTM) | $-2.76 | 133.90% |
| 2024 | $-1.18 | -0.84% |
| 2023 | $-1.19 | 88.89% |
| 2022 | $-0.63 | 57.50% |
| 2021 | $-0.40 | -35.48% |
| 2020 | $-0.62 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के लिए EPS
| कंपनी | EPS | EPS अंतर | देश |
|---|---|---|---|
| $17.32 | -727.54% |
US
|
|
| $-7.98 | 189.13% |
US
|
|
| $-5.29 | 91.67% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,105.07% |
NL
|
